Udai Banerji, Professor of Molecular Cancer Pharmacology at The Institute of Cancer Research, London, and Honorary Consultant in Medical Oncology, MBBS, MD, DNB, PhD, FRCP at The Royal Marsden NHS Foundation Trust, London, and Jonathan Pachter, PhD, Chief Scientific Officer at Verastem, talk about a study that found VS-6766, a unique inhibitor of the RAF/MEK signaling pathway, from Verastem Oncology, with a specific dosing regimen of 4 mg twice weekly, is tolerable and shows antitumor activity in patients with RAS mutant tumors.

свернуть